Digas Ngolo Tete

Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study

Victor Kande Betu Kumeso, Christelle Perdrieu, Caroline Menétrey, Médard Ilunga Wa Kyhi et autres

BACKGROUND: In previous clinical trials, oral fexinidazole treatment showed a favourable safety profile, while being easily administered and effective for most adult and paediatric patients with gambiense human African trypanosomiasis. The aim of this open-label cohort study was to investigate the effectiveness …

République démocratique du Congo, ch, Burkina Faso (code pays fourni par la source)

An Open-Label Study of the Effectiveness and Safety of Fexinidazole for Gambiense Human African Trypanosomiasis, Including an Exploration of Adherence in Outpatients

Victor Kande Betu Ku Mesu, Christelle Perdrieu, Caroline Menétrey, Médard Ilunga Wa Kyhi et autres

République démocratique du Congo, ch, Burkina Faso, Nigéria, Ouganda, Guinée, ae (code pays fourni par la source)

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial

Victor Kande Betu Kumeso, Wilfried Mutombo Kalonji, Sandra Rembry, Olaf Valverde Mordt et autres

BACKGROUND: Human African trypanosomiasis caused by Trypanosoma brucei gambiense (gambiense HAT) in patients with late-stage disease requires hospital admission to receive nifurtimox-eflornithine combination therapy (NECT). Fexinidazole, the latest treatment that has been recommended by WHO, also requires systematic admission to hospital, which …

République démocratique du Congo, ch (code pays fourni par la source)

Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial

Victor Kande Betu Kumeso, Wilfried Mutombo Kalonji, Clélia Bardonneau, Olaf Valverde Mordt et autres

BACKGROUND: Fexinidazole has been reported as an effective oral monotherapy against non-severe gambiense human African trypanosomiasis in a recent trial in adults. We aimed to assess the safety and efficacy of fexinidazole in children across all disease stages of gambiense human African …

République démocratique du Congo, ch (code pays fourni par la source)

Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study

Andrea Kuemmerle, Caecilia Schmid, Sonja Bernhard, Victor Betu Ku Mesu Kande et autres

BACKGROUND: Nifurtimox-eflornithine combination therapy (NECT) for the treatment of second stage gambiense human African trypanosomiasis (HAT) was added to the World Health Organization's Essential Medicines List in 2009 after demonstration of its non-inferior efficacy compared to eflornithine therapy. A study of NECT …

ch, République démocratique du Congo (code pays fourni par la source)

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clélia Bardonneau, Olaf Valverde Mordt et autres

BACKGROUND: Staging and treatment of human African trypanosomiasis caused by Trypanosoma brucei gambiense (g-HAT) required lumbar puncture to assess cerebrospinal fluid (CSF) and intravenous drugs that cross the blood-brain barrier for late-stage infection. These procedures are inconvenient in rural health systems of …

République démocratique du Congo, ch (code pays fourni par la source)

Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial

Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clélia Bardonneau, Olaf Valverde Mordt et autres

République démocratique du Congo, ch (code pays fourni par la source)

In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness

Caecilia Schmid, Andrea Kuemmerle, Johannes A. Blum, Salah Ghabri et autres

BACKGROUND: Trypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and insufficiently effective in certain areas (melarsoprol). Recently, nifurtimox-eflornithine combination …

ch, fr, République démocratique du Congo (code pays fourni par la source)